SUN PHARMA GLOBAL
PharmaSUN PHARMA GLOBAL is a pharmaceutical company focused on Neurology, Oncology, Immunology.
SUN PHARMA GLOBAL's Key Drugs
SUN PHARMA GLOBAL's core commercial portfolio centers on ILUMYA, spanning Neurology and Oncology — its most strategically important drugs approved in the last 15 years.
SUN PHARMA GLOBAL's Recent FDA Approvals
New NDA/BLA approvals for SUN PHARMA GLOBAL over the last two years — novel drugs only, excluding generics and label supplements.
SUN PHARMA GLOBAL's Therapeutic Areas
SUN PHARMA GLOBAL's approved drugs and pipeline span 3 therapeutic areas, led by Neurology and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SUN PHARMA GLOBAL's Top Competitors
SUN PHARMA GLOBAL's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SUN PHARMA GLOBAL Pipeline Snapshot
Active clinical trials for SUN PHARMA GLOBAL across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ILUMYA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2008-04-21
- Latest
- 2025-12-12
- Applications
- 13